Bayer’s non-hormonal therapy reduces hot flashes in Phase III trials
Bayer’s non-hormonal therapy, elinzanetant, reduced the frequency and severity of hot flashes associated with menopause in two Phase III trials.
![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/05/shutterstock_2252973645.jpg)
Bayer’s non-hormonal therapy, elinzanetant, reduced the frequency and severity of hot flashes associated with menopause in two Phase III trials.
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis
MMI pioneers Symani Surgical System in first US cases
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform